Pharmaceuticals, Biotechnology and Life Sciences
– Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of…
Program Aims to Improve Overall Survival in Advanced-Stage Cancers BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. announced initiation of the next phase of…
NEW YORK–(BUSINESS WIRE)–Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced the appointments…
Company Continues Progress on Reducing Carbon Footprint LONDON–(BUSINESS WIRE)–Walgreens Boots Alliance (Nasdaq: WBA) today announced the publication of its 2019…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the…
New Research Describes Novel Base Editors with Enhanced Editing Efficiency, Specificity, and Targeting Range CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics Inc. (Nasdaq:…
First clinical study evaluating DAV132 in patients Primary endpoint met: DAV132 was safe for use in hospitalized patients with several…
DUBLIN & VIENNA–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…
PARIS–(BUSINESS WIRE)–Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central…
New investor Fountain Healthcare Partners provides a further €5 M capital increase adding on the initial €39 M announced last…